ClinicaliQ Trial Snapshot
- Surveillance of Pancreatic Health After Diabetes Diagnosis — Recruiting • Non-phase study • Oncology • NCT06803771.
- The goal of this interventional study is to evaluate if the novel diagnostic blood test, called Avantect can early detect pancreatic cancer in patients diagnosed with type 2 diabetes within the last 6 months. Participants will: attend 3 study visits over 12….
- Sponsor: University Hospital Southampton NHS Foundation Trust.
Verify eligibility, endpoints and current status on the original source registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The goal of this interventional study is to evaluate if the novel diagnostic blood test, called Avantect can early detect pancreatic cancer in patients diagnosed with type 2 diabetes within the last 6 months. Participants will: * attend 3 study visits over 12 months time * provide a blood sample at each study visit * complete an anxiety questionnaire at each visit. Lead Sponsor: University Hospital Southampton NHS Foundation Trust Start Date: 2025-05-21 Primary Completion: 2028-02-28
Eligibility Snapshot
- : * 50 - 84 years of age at the time of enrolment (within year of birth, not month of birth) * Haemoglobin A1c (HbA1c) ≥ 48 or 6.5% and/or confirmed type II DM diagnosed within the last 180 days (+20 days flexibility allowance) * Willing to provide up to 30 mL of blood for each study visit * Willing and eligible to undergo MRI scan (or CT scan if MRI is contraindicated) * Understands the study process and is willing to take part in the study and sign the informed consent form
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.